The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19.

Henrietta PappEmese TóthJudit Bóvári-BiriKrisztina BánfaiPéter JuhászMohamed MahdiLilian Cristina RussoDávid BajuszAdrienn SiposLászló Petri Tibor Viktor SzalaiÁgnes KeményMónika MadaiAnett KuczmogGyula BattaOrsolya MóznerDorottya VaskóEdit HirschPéter BohusGábor MéhesJózsef TőzsérNicola J CurtinZsuzsanna HelyesAttila TóthNicolas C HochFerenc JakabGyörgy Miklós KeserűJudit E PongráczPéter Bai

Published in: British journal of pharmacology (2024)

These results point towards repurposing rucaparib for treating inflammatory responses in COVID-19.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
induced apoptosis
cell cycle arrest
dna damage
dna repair
endoplasmic reticulum stress
oxidative stress
signaling pathway
cell proliferation
pi k akt